Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Relapsed or Refractory Multiple Myeloma
NCT01646762
Terminated
This phase II trial studies how well paclitaxel albumin-stabilized nanoparticle formulation works in treating patients with multiple myeloma that has returned or did not respond to treatment. Drugs used in chemotherapy, such as paclitaxel albumin-stabilized nanoparticle formulation, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/14/2017
Locations: Mayo Clinic in Arizona, Scottsdale, Arizona
Conditions: Refractory Plasma Cell Myeloma
Register for Updates
Treatment Extension Study for Patients Who Have Previously Participated and Have Benefited From Iniparib in a Clinical Trial
NCT01593228
Completed
The purpose of this study is to assess the safety and tolerability of iniparib administered as monotherapy or in combination regimens in patients previously treated with iniparib in a clinical study and who have derived clinical benefit after completion of the parental study's objectives.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/12/2017
Locations: Investigational Site Number 840013, Birmingham, Alabama +31 locations
Conditions: Solid Tumors
Register for Updates
Doxorubicin Hydrochloride, Cyclophosphamide, and Filgrastim Followed By Paclitaxel Albumin-Stabilized Nanoparticle Formulation With or Without Trastuzumab in Treating Patients With Breast Cancer Previously Treated With Surgery
NCT00407888
Completed
RATIONALE: Drugs used in chemotherapy, such as doxorubicin hydrochloride, cyclophosphamide, and paclitaxel albumin-stabilized nanoparticle formulation, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Colony-stimulating factors, such as filgrastim, may increase the number of immune cells found in bone marrow or peripheral blood and may help the immune system recover from the side effects of chemotherapy. Monoclonal antibodie... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
08/30/2017
Locations: Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington
Conditions: Estrogen Receptor-positive Breast Cancer, HER2-positive Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer
Register for Updates
Carboplatin/Taxol/Ridaforolimus in Endometrial, Ovarian and Solids
NCT01256268
Completed
The purpose of this study is to: * Test the safety of a new investigational drug called MK-8669 (ridaforolimus) * Determine the maximum tolerated dose of MK-8669 * Determine the effectiveness of the maximum tolerated dose of MK-8669
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
08/29/2017
Locations: H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida
Conditions: Endometrial Cancer, Ovarian Cancer
Register for Updates
MK2206 and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Metastatic Breast Cancer
NCT01263145
Completed
This phase I trial studies the side effects and best dose of Akt inhibitor MK2206 (MK2206) when given together with paclitaxel and to see how well they work in treating patients with solid tumors that have spread to other places in the body and usually cannot be cured or controlled with treatment or breast cancer that has spread to other places in the body. Akt inhibitor MK2206 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy,... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/24/2017
Locations: Dana-Farber Cancer Institute, Boston, Massachusetts +2 locations
Conditions: Adult Solid Neoplasm, Recurrent Breast Carcinoma, Stage IV Breast Cancer
Register for Updates
Intraperitoneal Paclitaxel, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Stage III-IV Endometrial Cancer
NCT00575952
Completed
This phase I trial studies the side effects and best dose of intraperitoneal paclitaxel when given together with doxorubicin hydrochloride and cisplatin in treating patients with stage III-IV endometrial cancer. Drugs used in chemotherapy, such as paclitaxel, doxorubicin hydrochloride, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) and giving them in diffe... Read More
Gender:
FEMALE
Ages:
All
Trial Updated:
08/23/2017
Locations: Hartford Hospital, Hartford, Connecticut +8 locations
Conditions: Endometrial Adenosquamous Carcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Mixed Adenocarcinoma, Endometrial Serous Adenocarcinoma, Endometrial Squamous Cell Carcinoma, Endometrial Undifferentiated Carcinoma, Recurrent Uterine Corpus Carcinoma, Stage IIIA Uterine Corpus Cancer, Stage IIIC Uterine Corpus Cancer, Stage IVA Uterine Corpus Cancer, Stage IVB Uterine Corpus Cancer
Register for Updates
Carboplatin, Paclitaxel, and Bevacizumab in Treating Patients With Locally Recurrent or Metastatic Breast Cancer
NCT00654836
Completed
RATIONALE: Drugs used in chemotherapy, such as carboplatin and paclitaxel albumin-stabilized nanoparticle formulation, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry cancer-killing substances to them. Bevacizumab may also stop the... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/16/2017
Locations: Good Samaritan Cancer Care Center at Advocate Good Samaritan Hospital, Downers Grove, Illinois +5 locations
Conditions: Breast Cancer
Register for Updates
Paclitaxel and Capecitabine in Treating Women With Metastatic Breast Cancer
NCT00005649
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of paclitaxel and capecitabine in treating women who have metastatic breast cancer.
Gender:
FEMALE
Ages:
Between 18 years and 75 years
Trial Updated:
08/15/2017
Locations: PPD Development, Wilmington, North Carolina
Conditions: Breast Cancer
Register for Updates
Local Paclitaxel Delivery for SFA Disease
NCT00821028
Completed
To see if restenosis rates of superficial femoral artery atherosclerosis with percutaneous techniques can be improved using paclitaxel.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
08/14/2017
Locations: University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma
Conditions: Atherosclerosis, Angioplasty, Peripheral Arterial Disease
Register for Updates
Lapatinib Ditosylate, Trastuzumab, Paclitaxel, and Surgery in Treating Patients With Breast Cancer
NCT01688609
Completed
This phase II trial studies how well giving lapatinib ditosylate together with trastuzumab, paclitaxel, and surgery works in treating patients with breast cancer. Lapatinib ditosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as trastuzumab, can block tumor growth in different ways. Some block the ability of tumor to grow and spread. Others find tumor cells and help kill them or carry cancer-killing substances to them.... Read More
Gender:
FEMALE
Ages:
20 years and above
Trial Updated:
08/09/2017
Locations: M D Anderson Cancer Center, Houston, Texas +2 locations
Conditions: HER2-positive Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer
Register for Updates
Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage III Ovarian Cancer
NCT00004221
Terminated
Phase II trial to study the effectiveness of combination chemotherapy and peripheral stem cell transplantation in treating patients who have undergone surgery for stage III ovarian cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
08/08/2017
Locations: Gynecologic Oncology Group, Philadelphia, Pennsylvania
Conditions: Malignant Ovarian Mixed Epithelial Tumor, Ovarian Clear Cell Cystadenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Mucinous Cystadenocarcinoma, Ovarian Serous Cystadenocarcinoma, Primary Peritoneal Carcinoma, Stage III Ovarian Cancer, Undifferentiated Ovarian Carcinoma
Register for Updates
Ph 1 Study of VS-4718, a FAK Inhibitor, in Combination With Nab-paclitaxel and Gemcitabine in Advanced Cancer Subjects
NCT02651727
Terminated
The purpose of this study is to evaluate increasing dose levels of VS-4718 administered in combination with gemcitabine and nab-paclitaxel in subjects with advanced cancer and to determine a recommended Phase 2 dose (RP2D) for further development of this combination in subjects with untreated advanced pancreatic cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/25/2017
Locations: Washington University School of Medicine, Saint Louis, Missouri +1 locations
Conditions: Pancreatic Cancer
Register for Updates